Purespring Therapeutics, Ltd.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Purespring Therapeutics , a gene therapy company focused on transforming kidney disease treatment, has raised £80m ($105m) in a series B financing and selected a burgeoning blockbuster field - IgA nep

Executive changes in the off-patent medicines industry throughout 2023 reflected a growing interest in the innovator side of the life sciences sector among leading generics and biosimilars companies.

“I’m optimistic when it comes to both the integration and the impact of transformative technologies across the life sciences industry,” said Jessica Federer , Bayer ’s former chief digital officer a